A cutting-edge platform utilizing multi-epitope ligand-conjugated nanoparticles (MELNs) has been introduced to improve precision tumor targeting in cancer immunotherapy. By conjugating diverse tumor neoantigens on nanoparticle surfaces, MELNs facilitate enhanced immune recognition and activation. This approach aims to overcome tumor heterogeneity and immune evasion mechanisms, as detailed in a recent Medical Oncology publication. Such multifunctional nanomedicines represent a promising strategy to elevate immunotherapeutic efficacy with personalized antigen targeting.